vaccine is directed against Bacteria Mycoplasma gallisepticum. It causes chronic respiratory disease in chickens and infectious sinusitis in turkeys. infection can lead to lower egg production and economic losses in poultry farming.
A naturally attenuated strain of Bacteria was used to develop the product. According to the developer, its safety has been confirmed for young chicks. The company did not say when the application would be reviewed or when vaccines might possibly enter the EU market.
In March 2026, the product safety data received a positive assessment from the U.S. Department of Agriculture. The studies were conducted on chickens, turkeys and quail. They showed that vaccine strain remained stable and did not regain the ability to cause disease after sequential passage through chickens. Work on the registration of vaccines in the United States is continuing.
This is the second in-house vaccine from ECO Animal Health to be submitted for registration in the European Union. Sales of the company’s first product, ECOVAXXIN MS, against another cause of mycoplasma infections in poultry, began in July 2026.
